Cargando…

Neoadjuvant selpercatinib for advanced medullary thyroid cancer

BACKGROUND: Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Admin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jozaghi, Yelda, Zafereo, Mark, Williams, Michelle D., Gule‐Monroe, Maria K., Wang, Jennifer, Grubbs, Elizabeth G., Vaporciyan, Ara, Hu, Mimi I., Busaidy, Naifa, Dadu, Ramona, Waguespack, Steven G., Subbiah, Vivek, Cabanillas, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756223/ https://www.ncbi.nlm.nih.gov/pubmed/33169506 http://dx.doi.org/10.1002/hed.26527

Ejemplares similares

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer
por: Vodopivec, Danica M, et al.
Publicado: (2022)

MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier
por: Waguespack, Steven, et al.
Publicado: (2019)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid
por: Shojaie, Danielle, et al.
Publicado: (2021)

Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?
por: Waguespack, Steven G., et al.
Publicado: (2022)

MON-554 Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy
por: Agosto Salgado, Sarimar, et al.
Publicado: (2019)

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
por: Hamidi, Sarah, et al.
Publicado: (2023)

MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease
por: Gammons, Sarah, et al.
Publicado: (2020)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Recent advances and emerging therapies in anaplastic thyroid carcinoma
por: Cabanillas, Maria E., et al.
Publicado: (2018)

MON-491 TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center
por: Fazeli, Sasan, et al.
Publicado: (2020)

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
por: Nguyen, Ha, et al.
Publicado: (2021)

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
por: Busaidy, Naifa Lamki, et al.
Publicado: (2012)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
por: Ragnarsson, Oskar, et al.
Publicado: (2022)

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib
por: Turin, Christie Gloria, et al.
Publicado: (2021)

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
por: Sitbon, Marine, et al.
Publicado: (2022)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
por: Bardet, Stéphane, et al.
Publicado: (2022)

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
por: Hegde, Aparna, et al.
Publicado: (2020)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
por: Zhao, Xiao, et al.
Publicado: (2023)

Correction to: Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma
por: Wang, Jennifer Rui, et al.
Publicado: (2022)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics
por: Lu, Lina, et al.
Publicado: (2023)

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
por: Baek, Han-Sang, et al.
Publicado: (2023)

Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
por: Datar, Saumil, et al.
Publicado: (2020)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cvtuo2ngbpfm8681p1634v63lq